Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Courses Quicksearch

Search Now!

Courses


Course List
  • A Cut Above the Rest: Coordinating Perioperative Care Between Anesthesiologists and the PH Team

    Course ID: 2918
    Course Author: Traci Housten
    Course Author: Todd Kolb

    As patients with pulmonary hypertension live longer and better, it is inevitable that more PH patients will choose to undergo elective procedures or require emergency surgical procedures. Any operative procedure will require the involvement of several hospital departments. Thoughtful communication and collaboration between Anesthesia staff and the PH Team is crucial to develop a safe and proactive perioperative plan for the PH patient.


  • A Selective TGFß Ligand Trap Attenuates Pulmonary Arterial Hypertension

    Course ID: 2863




  • Advanced Care Planning: Talking to Patients and their Families about Advance Directives

    Course ID: 2912

    Despite advances in therapies, PH remains a progressive illness without a cure and we are limited to treating symptoms with the goal of quality-of-life enhancements. Palliative medicine is, by definition, a multidisciplinary approach to specialized medical care for people with serious illnesses. It focuses on providing patients with relief from the symptoms, pains, and physical/mental stress that accompany a serious illness. This session will provide an overview of palliative medicine, its benefits and limitations and how to incorporate a palliative care approach to the management of patients with PH.


  • Avoiding Infusion Confusion: The Safe Use of Infused Prostacyclins

    Course ID: 2776
    Course Author: Laura Duvall
    Course Author: Rebekah Hanson

    Infused prostacyclins for the treatment of PAH require highly specialized training, have unique administration, dosing, and monitoring requirements and are only accessible through a restricted distribution process. Inappropriate management due to lack of experience or unfamiliarity with the drug, devices or supplies has resulted in unnecessary adverse events including death. The purpose of the session is to provide practical guidance for the safe-use of infused prostacyclins to provide recommendations for clinicians to minimize the associated risks and potential for serious complications with these medications.


  • Battling the Blues: Depression and the PH Patient

    Course ID: 2737
    Course Author: Anthony McGuire

    Depression is an important comorbid condition that goes unrecognized in most patients with chronic disease. The physiologic effect of depression in the context of cardiovascular disease will be described along with how this may affect the pulmonary hypertension patient population. Simple screening techniques will be discussed along with the appropriate use of referrals once depression is discovered. Informal and formal depression treatment options will be presented.


  • CTEPH and CTED: Diseases that Hide in Plain Sight

    Course ID: 2830
    Course Author: Paul R. Forfia
    Course Author: Frances Rogers

    Chronic thromboembolic pulmonary hypertension (CTEPH) and chronic thromboembolic disease (CTED) are chronic sequelae of venous thromboembolism. In both cases, partial or complete obstruction of the pulmonary circulation leads to a syndrome of varying degrees of elevation of pulmonary arterial impedence, right ventricular afterload mismatch, dead space ventilation and hypoxemia. This session will highlight the salient as well as the subtle clinical and physiologic manifestations of this spectrum of disease. Often, the diagnosis evades initial testing, however with awareness, sufficient clinical suspicion, and proper application of imaging and physiologic testing, the ‘hidden’ diagnosis is easily uncovered.


  • CTEPH: Surgical Versus Medical Patient

    Course ID: 2844
    Course Author: William Auger

    The identification of patients with chronic thromboembolic pulmonary hypertension (CTEPH) is essential as this is a potentially curable form of pulmonary hypertension. This course will highlight the rationale and recommendation for screening all pulmonary hypertensive patients for CTEPH, and will outline the evaluation algorithm for establishing the diagnosis. Working with an experienced PTE surgery center to ascertain whether or not the chronic thromboembolic disease is operable will be emphasized. For those patients with nonsurgical disease, the treatment options of balloon pulmonary angioplasty and pulmonary hypertension targeted medical therapy will be reviewed.


  • Cardiac MRI

    Course ID: 2593
    Course Author: Tracy Frech
    Course Author: Promporn Suksaranjit
    Course Author: John Ryan

    Cardiac MRI
    At the conclusion of this educational activity, participants should have a deeper understanding of pulmonary arterial hypertension (PAH) through reviewing information provided by cardiac MRI that is helpful for PAH assessment, reviewing limitations of cardiac MRI, and reviewing potential applications of cardiac MRI for patients with systemic sclerosis.


  • Don't Be in Denial: Insurance and Disability Issues

    Course ID: 2772
    Course Author: Maribeth Duncan
    Course Author: Sharon Jones

    Assisting PH patients to get expensive medications or assisting them with disability can be a daunting task. Denial of PAH medications and disability benefits are unfortunately inevitable for many patients, and knowledge and skill is needed to overcome these obstacles. Learn tips to avoid denials and how to successfully win appeals, in addition to other resources available to assist patients with insurance and disability challenges.


  • Etiologies of PH Across the World

    Course ID: 2809
    Course Author: Christopher Barnett
    Course Author: Ghazwan Butrous
    Course Author: Vinicio de Jesus Perez
    Course Author: Erik Swenson

    This session will focus on four common causes of PAH around the world. From a global perspective, schistosomiasis is the most common cause of PH, with HIV and chronic high-altitude exposure closely behind. Drug and toxin exposure, however, has been identified as a specific problem in the western world. This class will highlight the key features of these particular types of PH/PAH, review both established and emerging paradigms, and discuss their implications on a global platform.


  • Evaluation and Management of Connective Tissue Disease-Associated Interstitial Lung Disease

    Course ID: 2928
    Course Author: Aryeh Fischer

    There are complex interactions between connective tissue disease (CTD) and interstitial lung disease (ILD), particularly in the PH patient. Clinicians that care for these patients will benefit from a deeper understanding of CTD and the ILD aspects of this diverse spectrum of disease. There are many clinical dilemmas to address and this course will focus on an approach to the evaluation and management of CTD-associated ILD.


  • Every Breath Counts: When to Involve Palliative Care

    Course ID: 2829
    Course Author: Stephen Mathai
    Course Author: Allyson Rupp

    Palliative medicine is, by definition, a multidisciplinary approach to specialized medical care for people with serious illnesses.This session will provide an overview of palliative medicine, its benefits and limitations and how to incorporate a palliative care approach into the management of patients with PH.


  • Filtering Through the Facts: Portopulmonary Hypertension

    Course ID: 2774
    Course Author: Traci Stewart
    Course Author: Joel Wirth

    This session will focus on portal hypertension (PoPH) and complications common to this patient population. A review of PAH medications and precautions specific to PoPH patients will be discussed. Nursing strategies specific to caring for PoPH patients will be explored.


  • From Bench to Bedside: Which Novel Pathways are Most Likely to be Harnesses Therapeutically in the Next 25 Years?

    Course ID: 2814
    Course Author: Eric Austin

    The past 30 years have produced tremendous advancements in the field of pulmonary hypertensive vascular disease (PHVD), particularly in pulmonary hypertension. The resultant improvements have bolstered patient quality of life and survival rates. In concert with this progress, there has been a renewed international effort amongst pediatric-focused clinicians to identify the similarities and differences between adult and pediatric patients and to highlight areas unique to the pediatric patient. This class will discuss these similarities and differences, with a particular emphasis on the Panama Classification for Pediatric Pulmonary Hypertensive Vascular Disease, and a focus its relevance to the pediatric patient.


  • Getting the Skinny on Bariatric Surgery

    Course ID: 2770
    Course Author: Michael Mathier
    Course Author: Sean M. Studer

    Obesity is an important health issue in the United States and appears to have a significant impact on the disease course, as well as the response to therapy, in at least some patients with pulmonary arterial hypertension (PAH). Bariatric surgery represents a significant risk in patients with PAH; however, it may be a worthwhile consideration when non-surgical weight loss strategies and maximizing PAH therapies have not achieved treatment goals. This session will explore our limited understanding of the relationship between obesity and PAH and describe what the field has learned from previous cases of successful bariatric surgery in patients with PAH.


  • Here We Grow Again: Regenerative Medicine

    Course ID: 2917
    Course Author: Duncan J. Stewart

    The fundamental problem in pulmonary arterial hypertension is a loss of lung blood vessels, such that the lung is no longer able to accommodate the cardiac output. Therefore, transformative improvement in pulmonary hemodynamics will require the repair or regeneration of lung microcirculation. This could be accomplished with the use of endothelial progenitor cells together with genetic manipulations or in combination with proteins or matrix. This session will provide an overview of the field, and review the challenges and opportunities of a regenerative medical therapy for this disease.


  • Imaging in PH: What Can a Picture Tell You?

    Course ID: 2817
    Course Author: John Ryan

    This course will discuss the role of imaging technology in the diagnostic and management process of pulmonary hypertension, specifically as it pertains to pulmonary arterial hypertension (PAH). Most patients are initially diagnosed using echocardiograms, however, in order to develop a specialized treatment plan more extensive imaging technologies such as CT, MRI, and PET scans are needed.


  • Interesting and Challenging Cases in PH

    Course ID: 2823

    The intricate manifestations of pulmonary hypertension can present many challenges. Participants in this educational activity will learn how to properly evaluate a patient for PH. This session also discusses in detail, the complex decisions surrounding PH treatment and the significance of right heart catheterization.


  • Interstitial Lung Disease in Systemic Sclerosis

    Course ID: 2927
    Course Author: Flavia Castelino

    Interstitial Lung Disease (ILD) is an important cause of morbidity and mortality in scleroderma patients. This presentation will discuss the clinical evaluation, diagnosis and management of scleroderma interstitial lung disease (SSc-ILD). It will cover the pathogenesis of scleroderma, new treatment targets and current clinical trials in SSc-ILD. Clinical cases will be used to illustrate key points in the evaluation and management of SSc-ILD.


  • Is It PAH or Not: Diagnostic Challenges

    Course ID: 2816
    Course Author: Ioana Preston

    While idiopathic pulmonary arterial hypertension is a rare disease, general PH often complicates other pulmonary and cardiovascular diseases and is a relatively common entity. Significant differences and similarities exist between the five groups of PH, as defined by the World Health Organization. However, without clinical context and noninvasive tests, there is no sufficient evidence to provide an accurate diagnosis. This class will focus on the how to differentiate between the various PH groups and how to utilize integrative tests to produce an accurate and effective diagnosis and treatment plan.


  • Keep Calm and Breathe On: Oxygen Use in PH

    Course ID: 2743
    Course Author: Tonya Zeiger




  • Making Sense of the Numbers: Understanding Complex PH through Advanced Hemodynamics

    Course ID: 2777
    Course Author: Lillian Hansen
    Course Author: Franz Rischard

    Right heart catheterization serves as a diagnostic tool in patients with pulmonary hypertension; however, its utility is not limited to diagnosis alone. Evaluation of hemodynamics is especially important in patients with complex pulmonary hypertension to understand etiology, response to therapy, and prognosis. In addition, full understanding of such patients’ hemodynamics relies upon utilizing other cardiopulmonary evaluation tools in conjunction with right heart catheterization. This topic serves to explore the challenges we all face in caring for patients with complex pulmonary hypertension and the various approaches available for hemodynamic evaluation and understanding of such patients.


  • Management of PH in the ICU

    Course ID: 2821
    Course Author: Yon Sung

    The management of critically ill patients with pulmonary hypertension can be particularly challenging as many of the treatments used in the ICU setting can exacerbate PH and right heart failure. In this class, we will review the unique aspects of the physiology of critically ill PH patients, which will then inform our approach to management. Specifically, we will discuss the role of invasive hemodynamic monitoring, the advantages and disadvantages of specific vasoactive medications, and the indications for pulmonary vasodilators in the acute setting.


  • PH Group III: Cases and Challenges

    Course ID: 2819
    Course Author: Oksana Shlobin

    This session will provide a case-centered update on pathogenesis and epidemiology and significance of pulmonary hypertension in parenchymal lung disease. The currently available treatment data and ongoing clinical trials will be discussed.


  • PHD2 Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension Recapitulating Clinical PAH

    Course ID: 2864




  • Panel Discussion: Enhancing Access to Drugs in Developing Countries, Challenges of Making Generic Drugs Available in Developing Countries

    Course ID: 2809
    Course Author: Steven Kawut
    Course Author: Mona Selej
    Course Author: Ghazwan Butrous
    Course Author: Talant Sooronbaev

    While idiopathic pulmonary arterial hypertension is a rare disease, general PH often complicates other pulmonary and cardiovascular diseases and is a relatively common entity. Significant differences and similarities exist between the five groups of PH, as defined by the World Health Organization. However, without clinical context and noninvasive tests, there is no sufficient evidence to provide an accurate diagnosis. This course will focus on the how to differentiate between the various PH groups and how to utilize integrative tests to produce an accurate and effective diagnosis and treatment plan.


  • Pediatric PAH Patients: How to Manage, How to Treat

    Course ID: 2824
    Course Author: Erika Rosenzweig




  • Rethinking Pediatric PH-International Aspects

    Course ID: 2813

    The past 30 years have produced tremendous advancements in the field of pulmonary hypertensive vascular disease (PHVD), particularly in pulmonary hypertension. The resultant improvements have bolstered patient quality of life and survival rates. In concert with this progress, there has been a renewed international effort amongst pediatric-focused clinicians to identify the similarities and differences between adult and pediatric patients and to highlight areas unique to the pediatric patient. This class will discuss these similarities and differences, with a particular emphasis on the Panama Classification for Pediatric Pulmonary Hypertensive Vascular Disease, and a focus its relevance to the pediatric patient.


  • Salvage Therapies in the U.S. and Europe versus Everywhere Else

    Course ID: 2812
    Course Author: Corey E. Ventetuolo
    Course Author: T. Pulido

    This session will focus on the definition and indications for interventional (surgical, non-surgical, and extracorporeal devices) strategies in patients with advanced PAH. It will discuss atrial septostomy, Pott's shunt, and current ECLS technologies as a bridging strategy to recovery or transplant in the context of global resources, restrictions, and limitations of organ donation.


  • Squeeze, Squeeze, Squeeze: The Importance of Right Ventricular Function and PH

    Course ID: 2775
    Course Author: Javier Jimenez

    Symptoms and Survival in patients with Pulmonary Hypertension is closely related to right ventricular function and performance. The purpose of this session is to understand the pathophysiology of right ventricular dysfunction. Imaging assessment of the right heart in adults, with a focus on echocardiography techniques and management techniques targeting right ventricular heart therapy will be reviewed.


  • The Accreditation Journey: PHCC Site Visit

    Course ID: 2906




  • The Hole Story: When to Consider Atrial Septostomy in the Adult with PAH

    Course ID: 2733
    Course Author: Barbara Prendes
    Course Author: Mark Rumbak

    The treatment of right heart failure in PAH is crucial to quality of life and overall survival from this disease. Atrial septostomy [AS] is a procedure to create an interatrial communication to decompress the right ventricle and augment systemic blood flow. Some Adults with PAH and progressive symptoms maybe a candidate for AS for quality of life and symptom improvement.


  • The Longest Mile: Invasive Cardiopulmonary Exercise Testing

    Course ID: 2741
    Course Author: David Systrom
    Course Author: Jeffrey Voner

    During this presentation, you will learn about the protocol, interpretation, barriers and benefits of this procedure. iCPET has a high success rate of identifying often elusive diagnoses of nonspecific symptoms, the most relevant to this conference being exercise-induced pulmonary hypertension (eiPH). Diagnosing PH in its intermediate stage (eiPH) through iCPET may improve patient outcomes through earlier treatment initiation. Unfortunately, iCPET is only provided by a few medical centers across the country.


  • Therapies for PAH: Transitions and Case Examples

    Course ID: 2820
    Course Author: Martha Kingman

    This class will discuss the basic principles for transitioning between PAH therapies. Several published transition methods will be presented. We will also be discussing helpful tips for managing side effects during transitions. The class will conclude with case studies describing transition methods used at the University of Texas Southwestern Medical Center at Dallas.


  • To SNF or Not to SNF: PH Therapies in Extended Care Facilities

    Course ID: 2789
    Course Author: Jacqueline Brewer
    Course Author: Jennifer Priziola
    Course Author: Samuel Allen

    Pulmonary arterial hypertension is a chronic disease beset by complications that may necessitate prolonged hospitalizations followed by the need for rehabilitation. However, many extended care facilities are not trained or able to manage the treatments for pulmonary arterial hypertension. In this session, we will discuss opportunities for error to occur during transitions of care, how to overcome them, and most importantly how to avoid them.


  • Transplanting in the PAH Patient: Screening and Evaluation for Lung Transplant

    Course ID: 2825
    Course Author: Fernando Torres

    The lung transplantation of a patient with PAH is very challenging. These patients carry the highest perioperative mortality of all lung transplant patients, but once the patients make it to one year, they tend to have one have one of the best long-term survivals. Thus, the selection of patients with PAH is critical for a successful transplant. In this section, we will concentrate on the screening and evaluation of patients with PAH to undergo lung transplantation.


  • Update on Classification, Screening, and Diagnosis of PH

    Course ID: 2815
    Course Author: C. Gregory Elliott




  • Updated Algorithm of PAH Treatment: Phrontline News

    Course ID: 2818
    Course Author: Mardi Gomberg-Maitland

    This course will discuss the current treatment algorithm based on guideline consensus. The new guidelines include the recently reported Phase 3 studies of macitentan, riociguat, and selexipeg. The session will cover general measures of care, and discuss monotherapy and combination therapy evidence-based data. The session will conclude with a discussion of remaining gaps in clinical care that need further evidence.


  • Variety is the Spice of Life: Combination Therapy for PAH

    Course ID: 2724
    Course Author: Martha Kingman
    Course Author: Steven Nathan

    In this session we will discuss expert consensus guidelines for the use of combination therapy in PAH. We will briefly review the combination therapy clinical trial data to date including results of the recent AMBITION trial. We will also discuss some drug-drug interactions between PH medications.


  • What Has Happened in the Last 25 Years: Global Perspectives/ 20 Years of Prostacyclins

    Course ID: 2807
    Course Author: Vallerie McLaughlin

    When the Pulmonary Hypertension Association was founded 25 years ago, treatment options for PAH patients were significantly limited. Though a small percentage of patients were eligible for calcium channel blockers, the average patient was treated with diuretics, digoxin, or warfarin. Modern therapies now address the three, well-characterized pathologic pathways. This session will provide a perspective on the treatment of PAH over the past 25 years.


  • What Have We Learned from Modern Worldwide Registries?

    Course ID: 2808
    Course Author: David Badesch

    Over the past decade, researchers across the world have performed registry studies with pulmonary hypertension (PH) patients. While the extrapolated data from these studies is limited, the results provide impactful and useful knowledge as it pertains to disease awareness, diagnosis, clinical care, and clinical trial design. This course will examine the information derived from modern global registries and how it has impacted the world of PH.